Evaluation of litholytic property of Japa Pushpa Churna in Cholelithiasis.

A Randomized controlled trial to evaluate the litholytic property of Japapushpa churna in Ashmari w.s.r. to Cholelithiasis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023293

Enrollment

Registered

2020-02-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K808- Other cholelithiasis

Interventions

Intervention1: Japapushpa Churna: Patients will be given Japapushpa Churna 5 grams, twice in a day with lukewarm water, 2 hours after the meal for three months trial period or till the dissolution of

Eligibility

Inclusion criteria

Inclusion criteria: 1.Ages ranging from 18 yrs. to 60 yrs 2.Those ready to give written informed consent 3.Asymptomatic or mildly symptomatic subjects with sonographic evidence of gallstones of size less than 15 mm in diameter, single or multiple 4.Gall stones, that are radiolucent on Plain abdominal X ray

Exclusion criteria

Exclusion criteria: 1.Current acute cholecystitis 2.Current or previous Obstructive Jaundice or Pancreatitis 3.Current or Previous use of UDCA 4.Known allergy or intolerance to UDCA 5.Existence of concurrent hepatic diseases 6.Participation in another study 7.Uncontrolled Hypertension and Diabetes Mellitus 8.Chronic alcoholics 9.HIV, HBsAg Positive patients 10.Mentally ill patients 11.Pregnancy or Lactation 12.Any other laboratory or clinical condition that could impact the outcome of the study or the safety of the patient

Design outcomes

Primary

Measure	Time frame
Gall stone resolution rate at 6th and 12th week will be evaluated by USG in all patientsTimepoint: 6th and 12th week	—

Secondary

Measure	Time frame
1.Improvement in number and severity of episodes of mildly symptomatic gallstones 2.Rate of surgical intervention 3.Sonographic improvement (size and number, presence of bile sludge, gallbladder wall thickness). 4.Evaluate tolerability and adverse effects of UDCA therapy and Japapushpa churna (including non-specific abdominal discomfort, rash or nausea) 5.Improvement in biochemical evidence of gallstone disease. (Reduced gamma-glutamyl-transpeptidase (GGT) and alkaline phosphatase (ALP)) Timepoint: 6th and 12th week	—

Measure

Time frame

1.Improvement in number and severity of episodes of mildly symptomatic gallstones 2.Rate of surgical intervention 3.Sonographic improvement (size and number, presence of bile sludge, gallbladder wall thickness). 4.Evaluate tolerability and adverse effects of UDCA therapy and Japapushpa churna (including non-specific abdominal discomfort, rash or nausea) 5.Improvement in biochemical evidence of gallstone disease. (Reduced gamma-glutamyl-transpeptidase (GGT) and alkaline phosphatase (ALP)) Timepoint: 6th and 12th week

—

Countries

India

Contacts

Public ContactDr Ravi Prakash

National Institute of Ayurveda

mita@ayu.in9414078872

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026